
Boston Scientific Corporation has announced that
it has received FDA approval for the REBEL™ Platinum Chromium Coronary Stent
System. This is company's latest generation bare-metal stent for the treatment
of coronary artery disease (CAD). Bare-metal stents continue to play an
important role in the treatment of CAD and represent a significant portion
of the global stent market. The company announced CE Mark for the Rebel
Stent System in February.
The REBEL Stent System expands the Boston
Scientific family of stents featuring its proprietary platinum chromium (PtCr)
alloy and a customized stent architecture design. The REBEL Stent offers
the identical stent platform as the Promus PREMIER™ Drug-Eluting Stent (DES)
but without the Everolimus drug.
"Bare-metal stents are an important part of our practice, as not every patient can receive a drug-eluting stent. This new bare-metal stent has the same great visibility and deliverability as the PREMIER DES but allows me to treat patients who are not candidates for DES therapy," said John C. Wang, M.D., of Medstar Union Memorial Hospital, Baltimore, Md. "In addition, the platinum chromium architecture provides great radial strength with low recoil, which is particularly important in patients receiving bare-metal stents."
"Boston Scientific is committed to developing the best treatment options for all patients with coronary artery disease," said Kevin Ballinger, president, Interventional Cardiology, Boston Scientific. "Launching the Rebel Stent System in the U.S. is another important step to ensure that we offer physicians the most differentiated and broadest product portfolio possible."
Of note, Dr. Wang presented data from the OMEGA clinical trial evaluating the REBEL Stent System in February at the Cardiovascular Research Technologies conference in Washington, D.C. OMEGA is a single arm, multi-center trial in the U.S. and Europe and the first reported results showed low event rates at nine months.
The REBEL Stent System is offered in a matrix of 46 sizes, ranging in diameter from 2.25 mm to 4.50 mm and lengths of 8 mm to 32 mm on a Monorail™ platform. This provides physicians with a range of options designed to best suit patient needs.
Source: Medindia
Advertisement
|
Latest Medical Gadgets




